Navigation Links
NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
Date:3/6/2008

ANN ARBOR, Mich., March 6 /PRNewswire/ -- NanoBio(R) Corporation has received its third $10 million tranche of equity funding from Perseus LLC, after having successfully met three critical development milestones: validating the efficacy and safety of its two topical treatments for skin infections and demonstrating the strength of its influenza vaccine in ferret studies.

The company, a spin-off from the University of Michigan, has received a total of $30 million over the past 18 months from Perseus LLC, a leading private equity management firm. The funding has enabled NanoBio to conduct phase 2 clinical trials on its two lead products, topical lotions NB-001 for herpes labialis (cold sores) and NB-002 for onychomycosis (nail fungus). Additionally, the funding has supported extensive animal studies supporting the company's nasal vaccines against influenza, hepatitis B and several additional pathogens.

Preliminary analyses of the data demonstrate the lotions have potent antiviral and antifungal effects without safety concerns or systemic absorption, according to NanoBio scientists.

Phase 2a and Phase 2b clinical trials on NB-001 are complete, while phase 2 clinical trials on NB-002 are in progress and will be completed by the first quarter of 2009. Final data will be presented after the data have undergone peer review processes.

"We're delighted by the considerable progress NanoBio has achieved in all dimensions, most notably its efficacy and safety data in the clinical realm," said Norman C. Selby, senior managing director at Perseus. "We are also pleased that the company has built a sound business infrastructure and a robust research program in the vaccine arena.

"The company's platform technology is proving to be highly effective in combating a broad range of viruses, bacteria and fungi, and we're eagerly anticipating the next round of data on its vaccine studies," he added.

Based on the positive data, NanoBio will move immediately to plan phase 3 testing of NB-001, said James R. Baker Jr., M.D., founder and chairman of NanoBio Corporation.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
2. CEL-SCI Corporation Reports First Quarter Financial Results
3. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
8. CEL-SCI Corporation Announces 2007 Financial Results
9. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been announced Jack Uldrich, ... events throughout the month of May. , Uldrich is the author of 11 books ... also frequently appears on the Science Channel’s FutureScape and Discovery Channel’s Inside Out. , ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Pets bring ... a token of appreciation, pet owners celebrate National Pet Week, which falls on the ... 2016, remind pet owners to cherish the human-animal bond and recognize responsible pet ownership. ...
(Date:5/2/2016)... ... , ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident Dr. ... at the Annual Meeting in Los Angeles. The first annual art forum was a ... Meeting attendees. , “Through art I hope to educate people about radiology and ...
(Date:5/2/2016)... ... 02, 2016 , ... Over $60 Billion is spent annually on products for ... leading product review site for Toys, Tots, Pets & More (TTPM) announced the 15 ... Showcase at the Metropolitan Pavilion in New York City. , Chosen from a field ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health ... Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their achievements in ... Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be ...
Breaking Medicine News(10 mins):